Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.49 |
| ▸ | SCN1A | P35498 | 5/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 5/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HNF4A | P41235 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389473 | 0.97 | BCAT2 (0.52) | SLC6A3MEN1KMT2ASMN1; SMN2BCAT2 | |
| SCHEMBL9531321 | 0.97 | BCAT2 (0.52) | SLC6A3MEN1KMT2ASMN1; SMN2BCAT2 | |
| Methylamine SCHEMBL28010440 | 0.93 | BCAT2 (0.53) | SLC6A3MEN1KMT2ASMN1; SMN2BCAT2 | |
| SCHEMBL1665535 | 0.92 | SLC6A3 (0.49) | SLC6A3MEN1KMT2ASMN1; SMN2BCAT2 | |
| SCHEMBL6900241 | 0.87 | SLC6A3 (0.68) | SLC6A3MEN1KMT2ASMN1; SMN2BCAT2 | |
| Alanine SCHEMBL27736021 | 0.86 | SCN1A (0.47) | SLC6A3MEN1KMT2ASMN1; SMN2BCAT2 | |
| SCHEMBL3558536 | 0.86 | SLC6A3 (0.48) | SLC6A3MEN1KMT2ASMN1; SMN2BCAT2 | |
| SCHEMBL517 | 0.85 | SLC6A3 (0.50) | SLC6A3MEN1KMT2ASMN1; SMN2BCAT2 | |
| SCHEMBL9373323 | 0.84 | SLC6A3 (0.49) | SLC6A3MEN1KMT2ASMN1; SMN2BCAT2 | |
| SCHEMBL5698693 | 0.83 | SLC6A3 (0.48) | SLC6A3MEN1KMT2ASMN1; SMN2BCAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0520423-B1 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6100252-A | SPECIFIED COMPOUNDS INCLUDING METHYL 2-BUTYL-1-((2'-(2-OXO-3H-1,2,3,5-OXATHIADIAZOL-4-YL)BIPHENYL) METHYL)-BENZIMIDAZOLE-7-CARBOXYLATE; USE TO TREAT CIRCULATORY DISEASES SUCH AS HYPERTENSIVE DISEASES AND HEART DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| US-5883111-A | STRONG AND LONG-LASTING ACTION BY ORAL ADMINISTRATION; HYPOTENSIVE AGENTS; CARDIOTONIC AGENTS; ALZHEIMER'S DISEASE; | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-16 | — | — | US | disclosed |
| US-5736555-A | HYPOTENSIVE AGENTS; FDA ORANGE BOOK LISTED PATENT FOR AZILSARTAN MEDOXOMIL | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-07 | — | — | US | disclosed |
| US-5583141-A | ADMINISTERING AS THERAPEUTIC AGENTS OF CIRCULATORY DISEASES; AZILSARTAN; ANGIOTENSIN II ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-10 | — | — | US | disclosed |
| US-5354766-A | 2-Ethoxy-1-((2'(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl)methyl)benzimidazole-7-carboxylic acid; hypotensive agents; CNS activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| US-5243054-A | Hypotensive agents, cardiovascular disorders or nervous system disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-07 | — | — | US | disclosed |
| EP-0520423-A2 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-30 | — | — | EP | disclosed |